Immunotherapies, such as monoclonal antibody therapy and checkpoint inhibitor therapy,
have shown inspiring clinical effects for the treatment of cancer. Chimeric antigen receptor T …

Multiple myeloma (MM), a bone marrow–resident hematological malignancy of plasma cells,
has remained largely incurable despite dramatic improvements in patient outcomes in the …

Precursor states of multiple myeloma (MM) and its native tumor microenvironment need in-
depth molecular characterization to better stratify and treat patients at risk. Using single-cell …

All cases of multiple myeloma (MM) are preceded by precursor states termed monoclonal
gammopathy of undetermined significance (MGUS) or smoldering myeloma (SMM). Genetic …

iNKT cells are a subset of innate-like T cells that utilize an invariant TCR alpha chain
complexed with a limited repertoire of TCR beta chains to recognize specific lipid antigens …

Natural killer T (iNKT) cells can help mediate immune surveillance against tumors in mice.
Prior studies targeting human iNKT cells were limited to therapy of advanced cancer and led …

Tumors originate from a number of genetic events that deregulate homeostatic mechanisms
controlling normal cell behavior. The immune system, devoted to patrol the organism against …

T cell lymphoma (TCL) is a highly heterogeneous group of diseases with a poor prognosis
and low 5-year overall survival rate. The current therapeutic regimens have relatively low …

Invariant natural killer T (iNKT) cells are potent immune cells for targeting cancer; however,
their clinical application has been hindered by their low numbers in cancer patients. Here …

γδ T cells are a distinct subset of T cells whose T cell receptors consist of γ chains and δ
chains, different from conventional αβ T cells. γδ T cells are considered as a member of the …